TL;DR: The Centers for Medicare & Medicaid Services modified NCD 90, the National Coverage Determination governing serum iron studies, effective March 7, 2026. Here's what billing teams need to act on now.
CMS serum iron studies coverage policy under NCD 90 has been updated. This policy covers ferritin, serum iron, total iron binding capacity (TIBC), and transferrin testing across a wide range of clinical indications — from iron deficiency anemia to hemochromatosis and chronic inflammatory conditions. This policy does not list specific CPT codes in the current documentation, so your billing team needs to confirm applicable codes through your Medicare Administrative Contractor before submitting claims.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Serum Iron Studies — NCD 90 |
| Policy Code | NCD 90 Medicare |
| Change Type | Modified |
| Effective Date | March 7, 2026 |
| Impact Level | Medium |
| Specialties Affected | Internal medicine, hematology, gastroenterology, nephrology, primary care, general surgery |
| Key Action | Audit iron study orders against updated indications list and confirm code mapping with your MAC before billing |
CMS Serum Iron Studies Coverage Criteria and Medical Necessity Requirements 2026
NCD 90 covers ferritin, serum iron, and either TIBC or transferrin when there is a clinically supported reason to evaluate iron metabolism. CMS serum iron studies coverage policy treats these as a working group — not standalone tests ordered reflexively.
The medical necessity bar here is real. CMS expects documentation that ties the order to a recognized clinical presentation. That means your orders need to connect to something specific: abnormal CBC values, active blood loss, suspected malabsorption, or a known condition associated with iron overload.
Iron Deficiency Indications
CMS identifies several clinical presentations that support medical necessity for iron studies when evaluating iron deficiency:
| # | Covered Indication |
|---|---|
| 1 | Decreased mean corpuscular volume (MCV) |
| 2 | Decreased hemoglobin or hematocrit when MCV is low or normal |
| 3 | Increased red cell distribution width (RDW) with low or normal MCV |
| 4 | Abnormal appetite, specifically pica |
| 5 | Acute or chronic gastrointestinal blood loss |
| 6 | Hematuria |
| 7 | Menorrhagia |
| 8 | Malabsorption |
| 9 | Status post-gastrectomy or post-gastrojejunostomy |
| 10 | Malnutrition |
| 11 | Preoperative autologous blood collection |
| 12 | Malignant, chronic inflammatory, and infectious conditions associated with anemia |
| 13 | Post-surgical blood loss without adequate iron replacement |
That last one is worth flagging. CMS specifically notes that patients may have iron-deficient erythropoiesis for months or years after major surgery if iron replacement was inadequate. That gives you a long documentation window — but only if the clinical record supports it.
Iron Overload Indications
For iron overload evaluation, CMS covers iron studies when any of the following are present:
| # | Covered Indication |
|---|---|
| 1 | Chronic hepatitis |
| 2 | Diabetes |
| 3 | Hyperpigmentation of skin |
| 4 | Arthropathy |
| 5 | Cirrhosis |
| 6 | Hypogonadism |
| 7 | Hypopituitarism |
| 8 | Impaired porphyrin metabolism |
| 9 | Heart failure |
| 10 | Multiple transfusions |
| 11 | Sideroblastic anemia |
| 12 | Thalassemia major |
| 13 | Cardiomyopathy, cardiac dysrhythmias, and conduction abnormalities |
Serum ferritin is specifically useful for both initiating and monitoring treatment for iron overload conditions like hemosiderosis and hemochromatosis. In those conditions, the iron level is elevated, TIBC and transferrin are within reference range or low, and percent saturation is elevated. Your documentation should reflect that pattern.
The Interpretation Problem
Here's the part the policy glosses over, but your billing team needs to understand. Ferritin and transferrin are acute phase reactants. In patients with active inflammation, infection, or recent surgery, iron studies are harder to interpret — and CMS acknowledges this directly. When a patient has a chronic inflammatory condition alongside potential iron deficiency, the results may point in conflicting directions.
That ambiguity doesn't mean the tests aren't covered. It means your documentation needs to show why the ordering provider needed this data despite the interpretive complexity. "Rule out iron deficiency in patient with chronic inflammatory anemia" is a defensible clinical rationale. "Iron studies" with no context is how you get a claim denial.
Timing and Specimen Quality
NCD 90 notes that iron studies are best performed when the patient is fasting in the morning and has abstained from medications that may alter iron balance. High-dose supplemental iron, for example, can falsely elevate serum iron. If your patient's results look unusual, this is worth checking before you bill for repeat testing — an abnormal result caused by iron supplementation isn't automatically grounds for additional workup reimbursement.
Prior Authorization
NCD 90 does not specify prior authorization requirements for serum iron studies under Medicare. That said, individual Medicare Advantage plans layer their own prior auth rules on top of NCD-level coverage. Check plan-specific requirements before assuming authorization is unnecessary, especially for serial monitoring orders in iron overload patients.
CMS Serum Iron Studies Exclusions and Non-Covered Indications
NCD 90 does not designate serum iron studies as experimental or investigational. The exclusions here are narrower — they're about frequency and context, not blanket non-coverage.
Repeat testing without documented clinical change is the primary risk. If a patient's iron studies are already established and stable, ordering a repeat panel without a new clinical trigger will draw scrutiny. "Routine monitoring" is not a sufficient medical necessity justification on its own.
Testing ordered solely because a patient is on oral contraceptives or is pregnant — which can elevate TIBC and transferrin — is unlikely to meet medical necessity unless there's a concurrent clinical concern driving the order. The policy notes these conditions as factors that affect test interpretation, not as independent indications for testing.
Coverage Indications at a Glance
| Indication | Status | Notes |
|---|---|---|
| Iron deficiency evaluation (low MCV, low hemoglobin/hematocrit, elevated RDW) | Covered | Document CBC abnormalities in the order |
| Pica | Covered | Link to abnormal appetite in clinical notes |
| Acute or chronic GI blood loss | Covered | Specify source and chronicity |
| Hematuria | Covered | Document in clinical record |
| Menorrhagia | Covered | Tie to anemia workup |
| Malabsorption syndromes | Covered | Include diagnosis in documentation |
| Post-gastrectomy / post-gastrojejunostomy | Covered | Reference surgical history |
| Malnutrition | Covered | Clinical diagnosis required |
| Preoperative autologous blood collection | Covered | Link to surgical prep documentation |
| Post-surgical blood loss without adequate iron replacement | Covered | Can span months to years post-op |
| Malignant, inflammatory, or infectious anemia | Covered | Distinguish from iron deficiency anemia — document interpretation challenge |
| Iron overload — hemochromatosis, hemosiderosis | Covered | Ferritin especially useful for treatment monitoring |
| Chronic hepatitis | Covered | Common iron overload workup indication |
| Multiple transfusions (iron overload surveillance) | Covered | Thalassemia major, sideroblastic anemia |
| Cardiac conditions related to iron overload (cardiomyopathy, dysrhythmias) | Covered | Document link to iron overload clinical picture |
| Routine monitoring without new clinical indication | Medical necessity documentation required | High denial risk without a documented clinical trigger — "routine monitoring" alone is not sufficient justification |
| Testing driven solely by pregnancy or OCP use (without clinical concern) | Medical necessity documentation required | These conditions alter TIBC but are not independent indications — document the concurrent clinical concern driving the order |
CMS Serum Iron Studies Billing Guidelines and Action Items 2026
This policy modification has a March 7, 2026 effective date. Here's what to do before and after that date.
| # | Action Item |
|---|---|
| 1 | Confirm your CPT code mapping with your MAC now. NCD 90 does not list specific CPT or HCPCS codes in the current policy documentation. Contact your Medicare Administrative Contractor directly and confirm which CPT codes map to ferritin, serum iron, TIBC, and transferrin under this NCD. Do not assume your existing charge capture is correct — verify it against what your MAC accepts under NCD 90 before the effective date. |
| 2 | Audit your order templates for serum iron billing. Check how your EHR or lab order system links iron study panels to diagnosis codes. Every panel order should pull a supporting ICD-10-CM code that maps to one of the covered indications above — confirm applicable diagnosis codes with your MAC or coding team. "Anemia, unspecified" alone is not your strongest argument — tie to a specific etiology when the record supports it. |
| 3 | Train your ordering providers on documentation requirements. The medical necessity criteria in NCD 90 require a clinical rationale tied to a specific presentation. Brief your internal medicine, hematology, and GI teams on what documentation triggers coverage. A sentence in the note tying the order to the clinical picture is all you need — but it has to be there. |
| 4 | Build a flag for repeat iron study orders. Serial testing in iron overload monitoring is covered, but only when clinically justified. Set up a review process for repeat orders on the same patient — especially for ferritin panels in hemochromatosis treatment. If there's no documented clinical change or response to treatment assessment, your claim denial risk is elevated. |
| 5 | Check Medicare Advantage plan policies separately. NCD 90 governs traditional Medicare. If you bill Medicare Advantage plans, pull their individual coverage policies for iron studies. Many MA plans follow NCD guidance but add frequency limits or prior authorization requirements. Confirm those plan-level rules before March 7, 2026. |
| 6 | Flag post-surgical patients in your billing workflow. CMS explicitly covers iron studies for patients who lost significant blood during surgery and didn't receive adequate iron replacement — and this coverage window can extend months or years post-op. Make sure your billing team doesn't incorrectly deny or downcode these claims due to the time gap between surgery and testing. |
If you're unsure how your patient mix maps to NCD 90's indications — especially in practices with high chronic disease or oncology volume — talk to your compliance officer before March 7, 2026. The intersection of inflammatory conditions and iron deficiency is where interpretation gets difficult and where documentation audits tend to focus.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Serum Iron Studies Under NCD 90
NCD 90 as currently published does not list specific CPT, HCPCS, or ICD-10 codes in the policy documentation. This is a meaningful gap for serum iron studies billing.
You should confirm applicable codes with your MAC for NCD 90 applicability:
Commonly Associated Lab Codes (Confirm With Your MAC)
| Code | Type | Description |
|---|---|---|
| Not listed in NCD 90 policy data | — | Confirm with your Medicare Administrative Contractor |
Your MAC's local coverage determination (LCD) or billing guidelines for laboratory services will specify which codes fall under NCD 90 coverage. Do not bill without that confirmation.
Why This Matters
When a national coverage determination omits specific codes, MACs have discretion in how they apply coverage. Two MACs in different regions may accept different code sets for the same policy. This is not hypothetical — it's a common pattern with lab NCD policies, and it's where billing teams get caught off guard.
Pull your MAC's LCD for laboratory services and cross-reference with NCD 90. If there's a conflict between LCD and NCD, the NCD governs — but you need to know what your MAC accepts before you submit.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.